StreetInsider.com News Articles

Form DEF 14A Cosmos Health Inc. For: Jun 02

Tue, 02 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260602/26592232.html

Form DEF 14A Cosmos Health Inc. For: Jun 02

Tue, 02 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260602/26592232.html

Cosmos Health discusses European Investment Bank financing talks

Tue, 02 Jun 2026 08:00:51 -0400

Cosmos Health Inc. (NASDAQ: COSM) reported its research and development division is in discussions with the European Investment Bank for financing of up to €25 million under the EIB's Venture Debt Program, according to a company statement.

The healthcare company said total liabilities decreased by $4.5 million, or 9.6%, quarter-over-quarter in Q1 2026, while stockholders' equity increased 7.6%. The liabilities-to-assets ratio improved by 370 basis points to 68.2% from 71.9% at year-end 2025.

Cosmos Health reported that 4,874,126 Series B Warrants expired unexercised, eliminating approximately 38% of total outstanding warrants. The company said this represents zero shareholder dilution.

The company stated its wholly-owned

Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajector

Tue, 02 Jun 2026 08:00:00 -0400

Significant Deleveraging: Total liabilities decreased by $4.5 million, or 9.6%, quarter-over-quarter, while stockholders' equity increased 7.6%
Landmark Financing: R&D division in discussions with the European Investment Bank for financing of up to €25 million
Capital Structure Simplification: 4,874,126 Series B Warrants expired unexercised, eliminating ~38% of total warrant overhang with zero shareholder dilution
Real Estate Value: Wholly-owned facilities independently valued at approximately $15 million — exceeding current market capitalization
Balance Sheet Transformation: Guidance projects stockholders' equity of $92.3 million by 2029, driven by a growing cash position of $62.9 million from internally generated cash flow

CHICAGO, June 02, 2026

Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajector

Tue, 02 Jun 2026 08:00:00 -0400

Significant Deleveraging: Total liabilities decreased by $4.5 million, or 9.6%, quarter-over-quarter, while stockholders' equity increased 7.6%
Landmark Financing: R&D division in discussions with the European Investment Bank for financing of up to €25 million
Capital Structure Simplification: 4,874,126 Series B Warrants expired unexercised, eliminating ~38% of total warrant overhang with zero shareholder dilution
Real Estate Value: Wholly-owned facilities independently valued at approximately $15 million — exceeding current market capitalization
Balance Sheet Transformation: Guidance projects stockholders' equity of $92.3 million by 2029, driven by a growing cash position of $62.9 million from internally generated cash flow

CHICAGO, June 02, 2026

Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajector

Tue, 02 Jun 2026 08:00:00 -0400

Significant Deleveraging: Total liabilities decreased by $4.5 million, or 9.6%, quarter-over-quarter, while stockholders' equity increased 7.6%
Landmark Financing: R&D division in discussions with the European Investment Bank for financing of up to €25 million
Capital Structure Simplification: 4,874,126 Series B Warrants expired unexercised, eliminating ~38% of total warrant overhang with zero shareholder dilution
Real Estate Value: Wholly-owned facilities independently valued at approximately $15 million — exceeding current market capitalization
Balance Sheet Transformation: Guidance projects stockholders' equity of $92.3 million by 2029, driven by a growing cash position of $62.9 million from internally generated cash flow

CHICAGO, June 02, 2026

Cosmos Health Provides Balance Sheet Update: Highlights European Investment Bank Financing Discussions for up to €25M, Eliminates 38% of Warrant Overhang with No Dilution; Reaffirms Growth Trajector

Tue, 02 Jun 2026 08:00:00 -0400

Significant Deleveraging: Total liabilities decreased by $4.5 million, or 9.6%, quarter-over-quarter, while stockholders' equity increased 7.6%
Landmark Financing: R&D division in discussions with the European Investment Bank for financing of up to €25 million
Capital Structure Simplification: 4,874,126 Series B Warrants expired unexercised, eliminating ~38% of total warrant overhang with zero shareholder dilution
Real Estate Value: Wholly-owned facilities independently valued at approximately $15 million — exceeding current market capitalization
Balance Sheet Transformation: Guidance projects stockholders' equity of $92.3 million by 2029, driven by a growing cash position of $62.9 million from internally generated cash flow

CHICAGO, June 02, 2026

Cosmos Health enters animal health market with C-Scrub wash

Mon, 01 Jun 2026 08:27:15 -0400

Cosmos Health Inc. (NASDAQ: COSM) announced plans to launch a veterinary formulation of its C-Scrub Wash 4% antimicrobial product, marking the company's entry into the animal health sector.

The company completed testing of C-Scrub Wash 4% according to European veterinary disinfectant standards EN 1656:2019 and EN 1657:2024. Testing conducted by Quality Assurance & Control Systems Ltd. in May 2026 demonstrated bactericidal activity against four reference organisms and yeasticidal activity against Candida albicans at both undiluted and 50% concentrations.

The product contains Chlorhexidine Digluconate 4% w/v as its active substance. Cosmos Health plans to launch the veterinary formulation initially in the United Kingdom,

Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657

Mon, 01 Jun 2026 08:25:00 -0400

CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the extension of its C-Scrub antimicrobial wash brand into the veterinary and animal health sector through the planned launch of a veterinary formulation of C-Scrub Wash 4%, marking the Company’s first entry into the animal health market.

The Company intends to launch the veterinary formulation in the United Kingdom, where C-Scrub is already an established and commercially active human-use brand, with broader international expansion

Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657

Mon, 01 Jun 2026 08:25:00 -0400

The Company intends to launch the veterinary formulation in the United Kingdom, where C-Scrub is already an established and commercially active human-use brand, with broader international expansion

Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657

Mon, 01 Jun 2026 08:25:00 -0400

The Company intends to launch the veterinary formulation in the United Kingdom, where C-Scrub is already an established and commercially active human-use brand, with broader international expansion

Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657

Mon, 01 Jun 2026 08:25:00 -0400

The Company intends to launch the veterinary formulation in the United Kingdom, where C-Scrub is already an established and commercially active human-use brand, with broader international expansion

Cosmos Health issues 2026-2029 guidance targeting $200m revenue by 2029

Tue, 26 May 2026 09:34:58 -0400

Cosmos Health Inc. (NASDAQ: COSM) announced financial guidance projecting revenue growth to $200.6 million by 2029, representing a 207% increase from $65.3 million in 2025. The diversified healthcare company expects to achieve profitability in 2027.

The guidance includes gross profit expanding to $71.2 million by 2029, up from $7.9 million in 2025, with gross margins improving from 12.1% to 35.5%. Net income is projected to reach $31.0 million by 2029, compared to a net loss of $19.1 million in 2025.

Cosmos Health expects adjusted EBITDA to grow from negative $3.4 million in 2025 to $44.2 million by 2029. Operating cash flow is

Cosmos Health issues 2026-2029 guidance targeting $200m revenue by 2029

Tue, 26 May 2026 09:34:58 -0400

Cosmos Health expects adjusted EBITDA to grow from negative $3.4 million in 2025 to $44.2 million by 2029. Operating cash flow is

Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash G